A-Alpha Bio Secures $20M Series A to Advance Yeast-Based Protein Interaction Platform
A-Alpha Bio raised $20 million in Series A funding and will apply its high-throughput yeast-based protein-protein interaction technology to drug discovery through partnerships with Twist Biopharma and Lumen Bioscience.
More: GeekWire, MedCity News
-
GeekWire / Charlotte Schubert: A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform
- MedCity News / Frank Vinluan: A-Alpha Bio raises $20M Series A to scale yeast-based platform that tests millions of protein-protein interactions